WO2004078712A3 - Isoquinoline derivatives and methods of use thereof - Google Patents
Isoquinoline derivatives and methods of use thereof Download PDFInfo
- Publication number
- WO2004078712A3 WO2004078712A3 PCT/US2004/005849 US2004005849W WO2004078712A3 WO 2004078712 A3 WO2004078712 A3 WO 2004078712A3 US 2004005849 W US2004005849 W US 2004005849W WO 2004078712 A3 WO2004078712 A3 WO 2004078712A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- isoquinoline derivatives
- isoquinoline
- effective amount
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006508867A JP2006520817A (en) | 2003-02-28 | 2004-02-26 | Isoquinoline derivatives and methods of use thereof |
AU2004218023A AU2004218023A1 (en) | 2003-02-28 | 2004-02-26 | Isoquinoline Derivatives and methods of use thereof |
EP04715130A EP1603568A4 (en) | 2003-02-28 | 2004-02-26 | Isoquinoline derivatives and methods of use thereof |
BRPI0407922-1A BRPI0407922A (en) | 2003-02-28 | 2004-02-26 | isoquinoline derivatives and methods of use of these |
CA002517358A CA2517358A1 (en) | 2003-02-28 | 2004-02-26 | Isoquinoline derivatives and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/376,746 US6956035B2 (en) | 2001-08-31 | 2003-02-28 | Isoquinoline derivatives and methods of use thereof |
US10/376,746 | 2003-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004078712A2 WO2004078712A2 (en) | 2004-09-16 |
WO2004078712A3 true WO2004078712A3 (en) | 2005-02-24 |
Family
ID=32961227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/005849 WO2004078712A2 (en) | 2003-02-28 | 2004-02-26 | Isoquinoline derivatives and methods of use thereof |
Country Status (11)
Country | Link |
---|---|
US (3) | US6956035B2 (en) |
EP (1) | EP1603568A4 (en) |
JP (1) | JP2006520817A (en) |
KR (1) | KR20050118168A (en) |
CN (2) | CN100400515C (en) |
AU (1) | AU2004218023A1 (en) |
BR (1) | BRPI0407922A (en) |
CA (1) | CA2517358A1 (en) |
PL (1) | PL378294A1 (en) |
RU (2) | RU2005130159A (en) |
WO (1) | WO2004078712A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
JP2007501857A (en) * | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | Tetracyclic benzamide derivatives and methods of use thereof |
US10425538B2 (en) * | 2003-10-06 | 2019-09-24 | Yellowpages.Com Llc | Methods and apparatuses for advertisements on mobile devices for communication connections |
US20050228007A1 (en) * | 2004-02-26 | 2005-10-13 | Prakash Jagtap | Isoquinoline derivatives and methods of use thereof |
RU2006134024A (en) * | 2004-02-26 | 2008-04-10 | Инотек Фармасьютикалз Корпорейшн (Us) | TETRACYCLIC DERIVATIVES OF LACTAM AND THEIR USE |
EP1784186A4 (en) * | 2004-06-16 | 2008-05-14 | Inotek Pharmaceuticals Corp | Methods for treating or preventing erectile dysfunction or urinary incontinence |
AU2006219023A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic Amino and Carboxamido Compounds and methods of use thereof |
WO2006093666A2 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Isoqunoline compounds and methods of use thereof |
JP2008531563A (en) * | 2005-02-25 | 2008-08-14 | イノテック ファーマシューティカルズ コーポレイション | Tetracyclic sulfonamide compounds and methods of use thereof |
WO2007008926A1 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
RU2008110955A (en) * | 2005-08-24 | 2009-09-27 | Инотек Фармасьютикалз Корпорейшн (Us) | INDENOISOCHINOLINONE ANALOGUES AND WAYS OF THEIR APPLICATION |
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
CA2677046A1 (en) * | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
EP2569307A2 (en) | 2010-05-10 | 2013-03-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
WO2013004652A1 (en) | 2011-07-04 | 2013-01-10 | Bayer Intellectual Property Gmbh | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants |
TWI519515B (en) | 2011-12-21 | 2016-02-01 | 諾維拉治療公司 | Hepatitis b antiviral agents |
JP5929229B2 (en) * | 2012-01-24 | 2016-06-01 | 東洋紡株式会社 | Alkaline phosphatase |
EA027280B1 (en) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
BR112015028538A2 (en) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | sulfamoylthiophenamide derivatives and their use as medicines for the treatment of hepatitis b |
NO3024819T3 (en) | 2013-07-25 | 2018-07-21 | ||
CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
RU2702109C1 (en) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Combined therapy for treating hepatitis b infections |
CN110483484A (en) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
CN107847762A (en) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
JP6832946B2 (en) | 2015-11-17 | 2021-02-24 | アエリエ ファーマシューティカルズ インコーポレイテッド | How to prepare kinase inhibitors and their intermediates |
EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
BR112019003945A2 (en) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | ophthalmic compositions |
EP3567044A4 (en) * | 2017-01-06 | 2020-06-10 | Korea University Research and Business Foundation, Sejong Campus | Novel quinolinone derivative and pharmaceutical composition for preventing or treating allergic disease such as asthma or atopy comprising same as active ingredient |
CN110506037A (en) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | Aryl cyclopropyl-amino-isoquinolin amide compound |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US96833A (en) * | 1869-11-16 | Improvement in barrel-filling- apparatus with whistling indicators | ||
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
IT1054655B (en) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | CONDENSED DERIVATIVES OF L ISOKINOLINE |
US4263304A (en) * | 1978-06-05 | 1981-04-21 | Sumitomo Chemical Company, Limited | 7 H-indolo[2,3-c]isoquinolines |
GB2025932B (en) | 1978-06-13 | 1982-10-27 | Sumitomo Chemical Co | Indoloisoquinolines and processes for producing them |
JPS57172923A (en) | 1981-04-17 | 1982-10-25 | Toray Ind Inc | Production of polybutylene terephthalate polymer fine particle |
GB8828806D0 (en) * | 1988-12-09 | 1989-01-18 | Beecham Group Plc | Novel compounds |
US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
US5597831A (en) * | 1991-08-29 | 1997-01-28 | Vufb A.S | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents |
CZ281473B6 (en) | 1991-08-29 | 1996-10-16 | Vúfb, A.S. | 2-HYDROXYETHYLAMINO SUBSTITUTED DERIVATIVES OF 5,11-DIOXO-5,6-DIHYDRO-11H-INDENO£1,2-c|ISOQUINOLINE, PROCESS PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF |
US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
US6346536B1 (en) * | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
JP2002515488A (en) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Carboxamide compounds, compositions, and methods for inhibiting PARP activity |
AU9298798A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
DE69940523D1 (en) | 1998-10-14 | 2009-04-16 | Purdue Research Foundation | NEW INDENOISOQUINOLINE AS ANTINEOPLASTIC AGENT |
US7781596B1 (en) | 1998-11-03 | 2010-08-24 | Abbott Laboratories | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
EP1140936B1 (en) | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
US6346535B1 (en) * | 1999-01-29 | 2002-02-12 | American Cyanamid Company | Fungicidal mixtures |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
US6790199B1 (en) | 2000-09-28 | 2004-09-14 | North American Medical Products, Inc. | Needle protective assembly for multi-draw needle |
ITMI20002358A1 (en) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | TIENO DERIVATIVES, 2, 3-C | ISOCHINOLIN-3-ONE AS INHIBITORS OF POLY (DP-RIBOSE) POLYMERASE |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
JP2003267888A (en) | 2002-03-15 | 2003-09-25 | Seishi Yoneda | Cardiac arrest fluid |
WO2004014862A1 (en) | 2002-08-09 | 2004-02-19 | Rutgers, The State University | Nitro and amino substituted heterocycles as topoisomerase i targeting agents |
JP2007501857A (en) * | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | Tetracyclic benzamide derivatives and methods of use thereof |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
SG150548A1 (en) | 2003-12-01 | 2009-03-30 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
US20050228007A1 (en) * | 2004-02-26 | 2005-10-13 | Prakash Jagtap | Isoquinoline derivatives and methods of use thereof |
-
2003
- 2003-02-28 US US10/376,746 patent/US6956035B2/en not_active Expired - Fee Related
-
2004
- 2004-02-26 CN CNB2004800114238A patent/CN100400515C/en not_active Expired - Fee Related
- 2004-02-26 AU AU2004218023A patent/AU2004218023A1/en not_active Abandoned
- 2004-02-26 RU RU2005130159/04A patent/RU2005130159A/en not_active Application Discontinuation
- 2004-02-26 KR KR1020057016094A patent/KR20050118168A/en not_active Application Discontinuation
- 2004-02-26 BR BRPI0407922-1A patent/BRPI0407922A/en not_active IP Right Cessation
- 2004-02-26 WO PCT/US2004/005849 patent/WO2004078712A2/en active Application Filing
- 2004-02-26 JP JP2006508867A patent/JP2006520817A/en active Pending
- 2004-02-26 CA CA002517358A patent/CA2517358A1/en not_active Abandoned
- 2004-02-26 CN CNA2007101991849A patent/CN101270087A/en active Pending
- 2004-02-26 PL PL378294A patent/PL378294A1/en unknown
- 2004-02-26 EP EP04715130A patent/EP1603568A4/en not_active Withdrawn
- 2004-10-12 US US10/963,293 patent/US7268143B2/en not_active Expired - Fee Related
-
2005
- 2005-07-08 US US11/177,161 patent/US7393955B2/en not_active Expired - Fee Related
-
2009
- 2009-11-27 RU RU2009144059/04A patent/RU2009144059A/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
HIREMATH S.P. ET AL.: "A new method for the synthesis of 6H,1 1 H-indolo[3,2-c]-isoquinolin-5-ones/thiones and their reactions", J. HETEROCYC. CHEM., vol. 30, no. 3, 1993, pages 603 - 609, XP002982444 * |
See also references of EP1603568A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1603568A4 (en) | 2009-02-25 |
US20040039009A1 (en) | 2004-02-26 |
US7393955B2 (en) | 2008-07-01 |
CN100400515C (en) | 2008-07-09 |
RU2005130159A (en) | 2006-03-27 |
US20050282848A1 (en) | 2005-12-22 |
CN101270087A (en) | 2008-09-24 |
US20050049270A1 (en) | 2005-03-03 |
EP1603568A2 (en) | 2005-12-14 |
CN1780625A (en) | 2006-05-31 |
PL378294A1 (en) | 2006-03-20 |
BRPI0407922A (en) | 2006-03-01 |
US6956035B2 (en) | 2005-10-18 |
US7268143B2 (en) | 2007-09-11 |
JP2006520817A (en) | 2006-09-14 |
RU2009144059A (en) | 2011-06-10 |
WO2004078712A2 (en) | 2004-09-16 |
AU2004218023A1 (en) | 2004-09-16 |
CA2517358A1 (en) | 2004-09-16 |
KR20050118168A (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078712A3 (en) | Isoquinoline derivatives and methods of use thereof | |
WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
IS2690B (en) | 5-Phenyl-4-methyl-thiazol-2-yl-amine derivatives that inhibit phosphatidyllineositol 3 kinase enzymes (PI3) to treat respiratory inflammatory diseases | |
MXPA03002814A (en) | Morpholin-acetamide derivatives for the treatment of inflammatory diseases. | |
WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
WO2006032342A3 (en) | Carbonyl compound-containing drug and the use thereof | |
WO2004075832A3 (en) | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof | |
WO2004080423A3 (en) | 7-amino- isoindolyl compounds amd their pharmaceutical uses | |
WO2008045664A3 (en) | Heterocyclic pde4 inhibitors as antiinflammatory agents | |
EP1711197A4 (en) | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions | |
WO2004108715A8 (en) | 3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity | |
ZA200510170B (en) | Method of reducing the harmful effects of orally or transdermally delivered nicotine | |
WO2004105737A3 (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2003053359A3 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005030753A3 (en) | Therapeutic agents useful for treating pain | |
WO2003057145A3 (en) | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES | |
WO2004047792A3 (en) | Liposomal glucocorticoids | |
YU87202A (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
WO2005105770A3 (en) | Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives | |
WO2009041787A3 (en) | Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease | |
AU2002233928A1 (en) | Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases | |
WO2008045663A3 (en) | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 378294 Country of ref document: PL Ref document number: 2517358 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 170523 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057016094 Country of ref document: KR Ref document number: 2006508867 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501559 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004218023 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4122/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004715130 Country of ref document: EP Ref document number: 2005130159 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2004218023 Country of ref document: AU Date of ref document: 20040226 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004218023 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048114238 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004715130 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057016094 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0407922 Country of ref document: BR |